Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ECE1 | P42892 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6139944 | 1.00 | KDM4E (0.41) | KDM4EMAPTHSD17B10GRM5HDAC1 | |
| SCHEMBL6139945 | 1.00 | KDM4E (0.41) | KDM4EMAPTHSD17B10GRM5HDAC1 | |
| SCHEMBL7068851 | 0.80 | KDM4E (0.38) | KDM4EMAPTHSD17B10GRM5HDAC1 | |
| SCHEMBL7068854 | 0.80 | KDM4E (0.38) | KDM4EMAPTHSD17B10GRM5HDAC1 | |
| SCHEMBL5227488 | 0.79 | GRM5 (0.36) | KDM4EMAPTHSD17B10GRM5HDAC1 | |
| SCHEMBL6140003 | 0.79 | GRM5 (0.36) | KDM4EMAPTHSD17B10GRM5HDAC1 | |
| SCHEMBL5227481 | 0.79 | GRM5 (0.36) | KDM4EMAPTHSD17B10GRM5HDAC1 | |
| SCHEMBL5227958 | 0.77 | KDM4E (0.43) | KDM4EMAPTHSD17B10GRM5HDAC1 | |
| SCHEMBL6139687 | 0.75 | KDM4E (0.37) | KDM4EMAPTHSD17B10GRM5HDAC1 | |
| SCHEMBL5231257 | 0.75 | KDM4E (0.37) | KDM4EMAPTHSD17B10GRM5HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187270-A1 | 16-Halogen-epothilone derivatives, method for producing them and their pharmaceutical use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-08-25 | — | — | US | disclosed |
| US-6930102-B2 | 16-halogen-epothilone derivatives, process for their production, and their pharmaceutical use | SCHERING AG (DE) | 2005-08-16 | — | — | US | disclosed |
| CN-1209360-C | 16-halogen-epothilones derivatives, preparation method and medical application thereof | SCHERIING AG (DE) | 2005-07-06 | — | — | CN | disclosed |
| US-20040014978-A1 | 16-halogen-epothilone derivatives, process for their production, and their pharmaceutical use | SCHERING AG (DE) | 2004-01-22 | — | — | US | disclosed |
| US-6610736-B1 | Antitumor | SCHERING AG (DE) | 2003-08-26 | — | — | US | disclosed |
| CN-1341115-A | 16-halogen-epothilones derivatives, preparation method and medical application thereof | SCHERIING AG (DE) | 2002-03-20 | — | — | CN | disclosed |
| EP-1150980-A2 | 16-HALOGEN-EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000049021-A2 | 16-HALOGEN-EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014978-A1 | 16-halogen-epothilone derivatives, process for their production, and their pharmaceutical use | EPOR, CYP2F1, REV1 | KDM4E 2205/4885MAPT 4595/4885HSD17B10 895/4885 |
| US-20050187270-A1 | 16-Halogen-epothilone derivatives, method for producing them and their pharmaceutical use | ABCB1, UGT2B17, CYP7B1 | KDM4E 3628/4885MAPT 3989/4885HSD17B10 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.